COMMUNIQUÉS West-GlobeNewswire

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

16/04/2025 - 13:00

WATERTOWN, Mass., April 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious [...]

Cullinan Therapeutics Receives Approval from European Medicines Agency to Initiate Phase 1 Trial of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Rheumatoid Arthritis

16/04/2025 - 13:00

Company-sponsored clinical trial will be initiated at FAU Erlangen-Nuremberg in Germany and Università Cattolica del Sacro Cuore, Rome in Q2 2025 CLN-978 is also being studied in the U.S., Europe, and Australia for [...]

Oxford Scientists Reveal Sunlight-Powered Anti-Cancer Breakthrough

16/04/2025 - 13:14

OXFORD, United Kingdom, April 16, 2025 (GLOBE NEWSWIRE) -- Dr. Daniel Chen, at the University of Oxford and Chief Scientist at biotech startup Oxperial BioHealth , revealed their major breakthrough in cancer prevention— [...]

Avicanna Announces Revocation of Management Cease Trade Order

16/04/2025 - 13:30

TORONTO, April 16, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“ Avicanna ” or “ Company ”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization [...]

LAVA Therapeutics Granted Full Waiver for RVO Payment Obligation

16/04/2025 - 13:30

Exemption from the $5.1 million repayment obligation strengthens LAVA’s balance sheet Underscores focus on cost curtailment and strategic option evaluation UTRECHT, The Netherlands and PHILADELPHIA, April 16, 2025 ( [...]

BriaCell Phase 2 Survival Data Beats Leading Standard in HR+ Breast Cancer

16/04/2025 - 13:30

Median overall survival of 17.3 months in Bria-IMT™ treated patients with hormone receptor positive (HR+) metastatic breast cancer markedly exceeds historical data of 14.4 months in TRODELVY ® (sacituzumab govitecan- [...]

Best Appetite Suppressants - Natural Over the Counter (OTC) Appetite Suppressant for Hunger Control & Fat Burner ( Men & Women) - By Phenq CrazyBulk in USA

16/04/2025 - 13:52

Albany, New York, April 16, 2025 (GLOBE NEWSWIRE) -- Struggling to control your appetite and cravings? You're not alone. Maintaining a healthy weight can be a constant battle in the modern world of tempting high-calorie [...]

Vaxartto Present at World Vaccine Congress Washington 2025 on April 23

16/04/2025 - 14:00

SOUTH SAN FRANCISCO, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, and Dr. James F. Cummings, Chief Medical Officer, [...]

Glucotrack to Participate in FORGETDIABETES, a Prominent European Research Initiative to Develop a Bionic Pancreas

16/04/2025 - 14:00

Continuous Blood Glucose Monitor will be integrated with automated insulin delivery system for major EU diabetes study RUTHERFORD, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” [...]

Addgene Adds Science and Tech Leaders to Its Management Team and Board of Directors

16/04/2025 - 14:00

Strategic appointments advance Addgene’s growth and market expansion strategy WATERTOWN, Mass., April 16, 2025 (GLOBE NEWSWIRE) -- Addgene , an organization empowering discovery by providing scientists with a vast [...]

Akari Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update

16/04/2025 - 14:00

Advancing development of next-generation precision Antibody Drug Conjugates (ADCs) to address multiple indications across a range of cancer types Continued progress of lead program, AKTX-101, for the treatment of solid [...]

Nautilus Biotechnology to Announce First Quarter 2025 Financial Results on April 29, 2025

16/04/2025 - 14:00

SEATTLE, April 16, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule proteome analysis platform, today announced it will report financial results [...]

electroCore to Participate at the Planet MicroCap Showcase

16/04/2025 - 14:00

ROCKAWAY, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate in the Planet [...]

Cocrystal Pharma to Present at Life Science Innovation Northwest 2025 Conference

16/04/2025 - 14:00

BOTHELL, Wash., April 16, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc . (Nasdaq: COCP) announces that Sam Lee, President and co-CEO, will present a Company overview at the Life Science Innovation Northwest (LSINW) [...]

Patent Granted to BC3 Technologies for SEAL Hemostatic Wound Spray

16/04/2025 - 14:00

-- FDA-Cleared Aerosolized Chitosan Hemostatic Agent Receives Patent for its Innovative Material and Method -- BALTIMORE, April 16, 2025 (GLOBE NEWSWIRE) -- BC3 Technologies, a Baltimore-based, minority-owned company [...]

OncoC4 Selected to Present at the 2025 AACR Meeting's Showcase Session

16/04/2025 - 14:00

Oral presentation will feature AI-081, a potentially best-in-class PD-1/VEGF bispecific antibody and ONC-841, a first-in-class anti-Siglec-10 antibody Initial clinical data for both AI-081 and ONC-841 in solid tumors [...]

MIMEDX to Host First Quarter 2025 Operating and Financial Results Conference Call on April 30

16/04/2025 - 14:00

MARIETTA, Ga., April 16, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the first quarter ended March [...]

Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Appoints Renowned MIT Professor Robert S. Langer to its Scientific Advisory Board

16/04/2025 - 14:00

Decoy’s development of novel peptide-conjugate therapeutics arising from its proprietary IMP3ACT™ platform to benefit from Dr. Langer’s extensive scientific knowledge and experience CAMBRIDGE, Mass. and HOUSTON, April [...]

BioVie Initiates SUNRISE-PD Clinical Trial Assessing Bezisterim in Early Parkinson’s Disease with First Patient Enrolled

16/04/2025 - 14:00

SUNRISE-PD evaluating the Company’s anti-inflammatory, insulin-sensitizing candidate bezisterim in patients with Parkinson’s disease who have not been treated with carbidopa/levodopa SUNRISE-PD is one of very few [...]